Abstract
Ideally, combination vaccines should not only be safe and effective, but also integrate smoothly into the vaccination schedule and provide advantages over the use of separately administered vaccines. Pentacel™ (Sanofl Pasteur Ltd., Toronto, Canada), a combination vaccine first licensed in Canada and subsequently in other countries, is immunogenic against diphtheria, tetanus, pertussis, pollo and Haemophilus influenzae type b when administered at 2, 4, 6 and 15-18 months of age. In published studies, the safety, immunogenicity and effectiveness of this combination vaccine were comparable with those of separately administered vaccines, with the advantage of a simplified dosing schedule.
Original language | English |
---|---|
Pages (from-to) | 793-805 |
Number of pages | 13 |
Journal | Expert Review of Vaccines |
Volume | 4 |
Issue number | 6 |
DOIs | |
State | Published - 1 Dec 2005 |
Externally published | Yes |
Keywords
- DTaP
- Diphtheria tetanus acellular pertussis vaccine
- Haemophilus influenzae type b (Hib) vaccine
- Immunizations
- Inactivated poliovirus vaccine
- Pentacel™
- Vaccine
ASJC Scopus subject areas
- Immunology
- Molecular Medicine
- Pharmacology
- Drug Discovery